H.C. Wainwright Downgrades Celladon Corp (CLDN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Celladon Reports Negative Results for CUPID2 Trial of MYDICAR(R) in Advanced Heart Failure
April 26, 2015 4:41 PM EDT- Investigational gene therapy fails to meet primary and secondary endpoints - - Investor conference call and webcast Monday at 8:30 a.m. ET (5:30 a.m. PT) -
SAN DIEGO, April 26, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq: CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR® (AAV1/SERCA2a) versus placebo added to a maximal, optimized heart failure drug... More
Celladon Reports Negative Results for CUPID2 Trial of MYDICAR(R) in Advanced Heart Failure
April 26, 2015 4:41 PM EDT- Investigational gene therapy fails to meet primary and secondary endpoints - - Investor conference call and webcast Monday at 8:30 a.m. ET (5:30 a.m. PT) -
SAN DIEGO, April 26, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq: CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR® (AAV1/SERCA2a) versus placebo added to a maximal, optimized heart failure drug... More
